What Is VMS in Menopause? Hot Flashes and Night Sweats Explained

What is VMS in menopause?

VMS is an abbreviation of vasomotor symptoms. “Vasomotor” refers to the nerves and muscles that control the width of your blood vessels; when those vessels open up suddenly near the skin, you get the flush of heat and the sweat that follows. In menopause care, VMS covers two closely related experiences:

• Hot flashes (hot flushes in British usage) — a sudden wave of heat, usually starting in the chest or neck and spreading upward to the face.
• Night sweats — the same event occurring during sleep, often heavy enough to wake you and soak nightclothes or bedding.

Together these two make up VMS, and they are the most recognisable symptoms of the menopause transition — as well as the ones most treatments are measured against. When a study reports that a therapy “reduced moderate to severe VMS by 60 percent”, it is counting hot flashes and night sweats.

What a single VMS episode actually feels like

A typical hot flash builds over seconds, peaks, and settles within about one to five minutes. Along with the heat you may notice visible flushing of the skin, sweating and a racing or pounding heartbeat. The part people rarely expect is the ending: once the sweat evaporates, many people feel suddenly cold and shivery. That chill is not a separate problem — it is the tail end of the same vasomotor event.

Why VMS happens: the thermostat explanation

The clearest way to understand VMS in menopause is to think about a thermostat that has become over-sensitive. VMS is not your body malfunctioning at random — it is a normal cooling reflex being triggered by an abnormally low threshold.

Your body maintains core temperature within a comfortable band sometimes called the thermoneutral zone. Inside that band you neither sweat to cool down nor shiver to warm up. As oestrogen levels fall during the menopause transition, the temperature-regulating centre in the hypothalamus behaves differently and that comfortable band narrows.^[1]

The consequence is mechanical rather than mysterious: a rise in core temperature far too small to bother you previously is now enough to cross the sweating threshold. Your body responds the way it would to genuine overheating — it opens the blood vessels near the skin and sweats hard to dump heat. That full-scale heat-loss response, triggered by a trivial provocation, is a hot flash. It also explains why a warm room, a hot drink, a spicy meal, alcohol or a stressful moment can all set one off: each nudges core temperature or blood flow just enough to breach a threshold that used to sit comfortably out of reach.

The signalling pathway behind the newer medicines

Research over the past decade has focused on a group of neurons in the hypothalamus known as KNDy neurons, named for three substances they produce together: kisspeptin, neurokinin B and dynorphin. Oestrogen normally restrains these neurons. When oestrogen declines, they enlarge and become more active, and neurokinin B signalling through the NK3 receptor appears to drive the heat-loss response that we experience as a flush.^[2]

This matters practically, not just academically: it is the reason a new class of non-hormonal drugs exists. Neurokinin-receptor antagonists were designed to interrupt exactly this pathway, which is how they reduce hot flashes without using hormones at all.^[2]

How common is VMS, and how long does it last?

Around three quarters of women experience vasomotor symptoms at some point in the menopause transition, and roughly a third describe their VMS as moderate to severe — frequent enough or intense enough to interfere with sleep, work or daily life.

Duration is where expectations and evidence diverge most sharply. Many people are told, or assume, that hot flashes last a year or two. The largest long-term study to follow women through the transition — which tracked frequent symptoms, meaning six or more days in the preceding fortnight — tells a different story:^[3]

The pattern worth noticing is the last one: the earlier VMS starts, the longer it tends to run. For women whose symptoms begin while periods are still occurring, median duration exceeded a decade — and persisted a median of over nine years beyond the final period. For those whose symptoms only appear after the final period, the course was substantially shorter, at around three and a half years.^[3]

Two practical points follow. First, if your hot flashes have gone on for years, that is common rather than abnormal. Second, timelines are population medians — individual experience ranges from a few months to well over a decade, and averages should not be used to talk anyone out of treatment they need now.

What actually helps VMS

Treatment choice depends on how severe your VMS is, your medical history and what you are comfortable with. Mild VMS may need nothing more than practical adjustments; frequent or disruptive VMS deserves a proper conversation about medication. The realistic options fall into three groups.

1. Hormone therapy

Menopausal hormone therapy remains the most effective treatment for VMS, and also prevents bone loss and fracture.^[7] It is not suitable for everyone — a personal or family history of certain cancers, blood clots or cardiovascular events changes the calculation — and both the type of hormone and the timing of starting it affect the balance of benefit and risk. This is a decision to make individually with a clinician, not from a website.

Timing matters more than most coverage suggests. For women under 60, or within 10 years of menopause, who have no contraindications, the balance of benefit and risk favours treatment for bothersome VMS. Starting more than 10 years after menopause, or after 60, shifts that balance unfavourably, because the absolute risks of coronary heart disease, stroke, blood clots and dementia are higher by then.^[7] That is why the same treatment can be a reasonable option at 52 and a poor one at 65.

2. Non-hormonal prescription options

For people who cannot or prefer not to take hormones, several prescription medicines have evidence for reducing VMS:

• Neurokinin-receptor antagonists — the newest class, developed specifically to block the KNDy/NK3 pathway described above.
• Certain antidepressants (SSRIs and SNRIs at doses used for hot flashes rather than for depression).
• Gabapentin and related medicines, which some people find particularly useful for night-time symptoms.
• Other options such as oxybutynin or clonidine, used more selectively.

Availability, licensing and brand names differ by country, and the field is moving quickly — check current options with your own prescriber.^[6]

3. Non-drug approaches with real evidence

These are often presented as an afterthought, but two of them have genuine trial support:

• Cognitive behavioural therapy (CBT) — does not necessarily reduce how often flushes occur, but reliably reduces how distressing and disruptive they are.
• Clinical hypnosis — has performed well in controlled studies of hot flash frequency and severity.^[4]
• Weight management, where relevant, is associated with improvement in symptom burden.
• Practical trigger management — layered clothing you can remove quickly, a cooler bedroom, cool water within reach, and identifying your own personal triggers rather than assuming everyone shares the same ones.

Supplements: what “not recommended” actually means

Menopause guidelines do not recommend supplements and herbal remedies for hot flashes, including black cohosh, soy foods and soy extracts.^[4] That is worth stating plainly. But it is also worth understanding what the wording means, because it is routinely misreported in both directions.

The Menopause Society grades its recommendations by strength of evidence, and soy sits at Level II, defined as “limited or inconsistent scientific evidence”.^[4] Inconsistent is the operative word. It is not the same finding as “tested and shown to do nothing”. Some trials have reported benefit — including a randomised trial in Japanese postmenopausal women — while others have not.^[5] A guideline cannot recommend a treatment on that basis, and it is right not to. That is a different statement from saying nobody responds.

There is a plausible reason results might scatter this way. Soy isoflavones are thought to work largely through equol, a compound produced when gut bacteria metabolise them — and not everyone’s gut flora does that efficiently. If that turns out to matter, a trial averaging responders and non-responders together would show exactly the muddled picture we see. This is an open question rather than a settled mechanism.

The practical position, then: soy is not a substitute for a treatment with good evidence behind it, and anyone selling it as one is going beyond what is known. But if you take it and find it helps, that is not necessarily a placebo, and if it does nothing for you, that is not a failure on your part. Evidence for acupuncture is similarly inconsistent.^[4] What the data do not support is the confident language used to market any of them.

Why you are suddenly seeing the term VMS everywhere

Search interest in the phrase “VMS menopause” was close to flat for years and then rose sharply from 2024 onward. The most likely explanation is straightforward: as non-hormonal treatments developed specifically for vasomotor symptoms came to market, the clinical abbreviation moved out of journals and into patient information, consultations and advertising. A term that used to appear mainly in research is now printed on materials aimed at the public — so people encounter “VMS”, do not recognise it, and search for it.

If that is how you arrived here, the short answer is at the top of this page: it is simply the clinical name for the hot flashes and night sweats you already know.

What VMS does not cover

VMS is one part of the menopause picture, not the whole of it. The transition can also involve sleep disturbance independent of night sweats, mood and anxiety changes, brain fog, joint and muscle aches, and the group of vaginal and urinary changes clinicians call the genitourinary syndrome of menopause. None of those are classed as vasomotor symptoms, and treatments that work well for VMS do not automatically address them — which is worth knowing before concluding that a treatment has failed.

The genitourinary changes are worth singling out, because they behave differently from hot flashes in two ways. They affect somewhere between roughly a quarter and four-fifths of women after menopause, and unlike VMS they tend to persist or worsen rather than settle with time. They also have their own treatments — vaginal moisturisers and lubricants for milder symptoms, and low-dose vaginal oestrogen, vaginal DHEA or ospemifene for moderate to severe ones — which work locally and are considered separately from whether you take anything for hot flashes.^[8] They remain widely underdiagnosed and undertreated, largely because they go unmentioned.